Comparison Smart Pilot and YpsoMate On

News – Ypsomed Delivery Systems

To serve different market needs and use cases, Ypsomed has developed a portfolio of connected injection devices. The portfolio can be divided into two broad device categories: connected add-ons, such as SmartPilot for YpsoMate, and Injectors with integrated connectivity, such as YpsoDose and YpsoMate On.

News – Ypsomed Delivery Systems

Burgdorf – Ypsomed has introduced the world’s first autoinjector for prefilled syringes with integrated connectivity. The YpsoMate On combines the advantages of the proven YpsoMate autoinjector with the options of digital therapy support. The YpsoMate On follows an eco-design principle which allows easy recycling of electronic components and encourages the use of sustainable components.

Alliance to Zero founded to achieve net zero emissions across the pharmaceutical supply chain

News – Ypsomed Delivery Systems

Burgdorf – Today, eight companies representing the pharmaceutical supply chain for pharma products announced the founding of the Alliance to Zero, a non-profit membership association for pharma and biotech supply chain companies that aims to facilitate the transition of the pharma sector to compliance with net zero emissions in line with the goals of the Paris Climate Agreement.

Compelling design enables simple adherence monitoring

News – Ypsomed Delivery Systems

Ypsomed has been successful in the Red Dot Award: Product Design 2021. An international jury of experts has awarded SmartPilot for the UnoPen pen injector the distinction “Red Dot”, which stands for high design quality.

News – Ypsomed Delivery Systems

Burgdorf / Mainz / Basel – Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the development, manufacturing and testing of pharmaceuticals. In a joint effort, the three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. This solution should enable pharmaceutical companies to quickly bring biopharmaceuticals in a patch injector into the clinical trial stage and to the market. For patients, the solution reduces the number of hospital visits required for treatment.